First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results

Peter Schmid, Nicholas C. Turner, Carlos H. Barrios, Steven J. Isakoff, Sung Bae Kim, Marie Paule Sablin, Shigehira Saji, Peter Savas, Gregory A. Vidal, Mafalda Oliveira, Joyce O'Shaughnessy, Antoine Italiano, Enrique Espinosa, Valentina Boni, Shane White, Beatriz Rojas, Ruffo Freitas-Junior, Yeesoo Chae, Igor Bondarenko, Jieun LeeCesar Torres Mattos, Jorge Luis Martinez Rodriguez, Lisa H. Lam, Surai Jones, Sarah Jayne Reilly, Xiayu Huang, Kalpit Shah, Rebecca Dent

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Fingerprint

Dive into the research topics of 'First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science